All In Biotech

Drug Trial Radar · NCT03927703

A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC

A Phase 3 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy and Safety of SB206 and Vehicle Gel Once Daily in the Treatment of Molluscum Contagiosum

Last checked: Nov 19, 2026Latest source record: Mar 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 355 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

355

Actual

Start

Jun 13, 2019

Primary completion

Nov 11, 2019

Study completion Feb 3, 2020

Sponsor

Lead sponsor
Novan, Inc.Industry
Sponsor type
Industry
Collaborators
Synteract, Inc.
First posted
Apr 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in up to approximately 340 subjects ≥6 months of age with MC. Subjects or their caregivers will apply SB206 12% or Vehicle Gel once daily for a minimum of 4 weeks and up to 12 weeks to all lesions identified at Baseline and new treatable lesions that arise during the course of the study.

Conditions

  • Molluscum Contagiosum

Interventions

  • SB206 12%Drug

    Topically once daily

  • PlaceboDrug

    Topically once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Clearance of All Treatable MC at Week 12Time frame: 12 Weeks

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • Site #266

    Scottsdale, Arizona

  • Site #101

    Hot Springs, Arkansas

  • Site #282

    Beverly Hills, California

  • Site #113

    San Diego, California

  • Site #257

    Thornton, Colorado

  • Site #268

    Boynton Beach, Florida

  • Site #292

    DeLand, Florida

  • Site #278

    Miami, Florida

  • Site #305

    Tampa, Florida

  • Site #175

    New Albany, Indiana

  • Site #294

    Owensboro, Kentucky

  • Site #289

    Metairie, Louisiana

  • Site #297

    New Orleans, Louisiana

  • Site #275

    Largo, Maryland

  • Site #274

    Clarkston, Michigan

  • Site #121

    Fridley, Minnesota

  • Site #206

    Omaha, Nebraska

  • Site #304

    Portsmouth, New Hampshire

  • Site #201

    Berlin, New Jersey

  • Site #108

    Rochester, New York

  • Site #309

    Portland, Oregon

  • Site #255

    Mt. Pleasant, South Carolina

  • Site #271

    Knoxville, Tennessee

  • Site #167

    Houston, Texas

  • Site #293

    Plano, Texas

  • Site #281

    Syracuse, Utah

  • Site #267

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.